cyrilzakka/clinical-trials huggingface dataset:
Expectations of Patients in Palliative Situation

To date, there is a lack of data about the benefit of blood cell transfusions for patients diagnosed of a hematologic malignancy who are not eligible for curative treatments. Furthermore, there is no clear guideline about how to transfuse these patients and when the blood cell transfusions should be stopped.

Allogenic stem cell transplantation is nowadays the only curative treatment for patients with high-risk myeloid neoplasms. Knowing that the median age at diagnostic for acute myeloid leukemia is 68 years and this incidence increases after 65 years, a lot of patients won't be eligible for allogenic stem cell transplantation.

Besides, patients with haematologic malignancies are prone to cytopenias, due to their pathology and the treatments used to limit its progression. A study estimate that these patients need a median of 4 blood cell units per month, and it is known that repeated transfusions are associated with an increased risk of dying in hospital.

Finally, it is estimate that there was a lack of 20 000 blood cell units in France in 2022.

It therefore seems essential to find ways to optimize blood transfusion prescriptions in this population of patients who won't be eligible for curative treatments, with the main idea of maintaining or even improving their quality of life.

The investigators will study the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions, by asking them if whether or not they believe that the transfusion planed to be administer will benefit the patient. To do this, investigators will distribute questionnaires before each blood cell transfusions to patients who will be included, to the paramedic who administered the transfusion and to the physician who prescribed the transfusion.

It is to investigators knowledge the first study to compare the expectations of patients in palliative situation, paramedics and medical staff concerning blood cell transfusions in hematology department, and follow the evolution of these expectations prospectively.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years or more AND
* Diagnosed of an intermediate or high-risk acute leukemia and not eligible for allogenic stem cell transplantation Or
* Diagnosed of a high-risk myelodisplasic syndrome and not eligible for allogenic stem cell transplantation Or
* Diagnosed of an intermediate or high-risk myelofibrosis and not eligible for allogenic stem cell transplantation Or
* Diagnosed of a chronic myeloid leukemia in blast crisis phase and not eligible for allogenic stem cell transplantation Or
* Relapsing after allogenic stem cell transplantation and not eligible for a second allogenic stem cell transplantation

Exclusion criteria:

* Patients who can't read
* Patients who can't write
* Patients who can't express their consent
Tobacco Retraining of Automatic Approach to Treat Individuals With Tobacco Dependence and Severe Concurrent Disorders.

A randomized control trial evaluating a novel smoking cessation intervention in individuals at a an inpatient clinic for clients with addiction and concurrent disorders. The intervention is based on cognitive bias modification, where participants are explicitly or implicitly trained to make avoidance movements by pushing a joystick in response to pictures of smoking, and as a result altering their cognitive biases towards smoking and tobacco dependence.

Hypothesis: Participation in the experimental (tobacco-avoidance) condition will induce reduction of smoking, assessed as lower levels of carbon monoxide measured at baseline and 12 week follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Proficiency to read and write english
* A minimum score of 5 or higher on the fagerström test for nicotine dependence, indicating a medium dependence
* Current smoking will be validated by Carbon monoxide breath monitor

Exclusion Criteria:

* Patients not yet stabilized enough to allow for regular participation in the intervention
Prospective Study of Pain After Spinal Morphine for Cesarean Section and Factors Involved in Moderate to Severe Pain

Spinal block with intrathecal morphine is a popular anesthetic technique in cesarean delivery. This technique brings about good maternal and neonatal outcomes as well as provides good postoperative pain control. Systematic review showed intrathecal morphine produced long period of pain control up to 27 hours. However, some patients still experienced moderate to severe pain which defined as postoperative pain score \>,= 4. From our institute survey, there were more than 50 percents of patients undergoing cesarean delivery receiving spinal block with intrathecal morphine experienced moderate to severe pain in the first 24 hours.

The aim of the study is to determine the actual incidence and associated factors of patients whom experienced moderate to severe pain after spinal anesthesia with intrathecal morphine 200 mcg in cesarean delivery.

Spinal block with intrathecal morphine is a popular anesthetic technique in cesarean delivery. This technique brings about good maternal and neonatal outcomes as well as provides good postoperative pain control. Systematic review showed intrathecal morphine produced long period of pain control up to 27 hours. However, some patients still experienced moderate to severe pain which defined as postoperative pain score \>,= 4. From our institute survey, there were more than 50 percents of patients undergoing cesarean delivery receiving spinal block with intrathecal morphine experienced moderate to severe pain in the first 24 hours. Failure in achieve adequate pain control results in poor maternal satisfaction, effect breast feeding and may lead to chronic wound pain.

The aim of the study is to determine the actual incidence of patients whom experienced moderate to severe pain after spinal anesthesia with intrathecal morphine 200 mcg in cesarean delivery. Also, factors that may involved moderate to severe postoperative pain will be analyzed and reported.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Elective cesarean section
* Patient accept spinal anesthesia
* ASA classification I-II
* Understand numerical rating scale for pain score

Exclusion Criteria:

* Not understand Thai
* Contraindicated in spinal anesthesia with intrathecal morphine
* Complicated pregnancy that general anesthesia may required for cesarean delivery
Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene


Eligibility Criteria:
Inclusion Criteria:

* Healthy young subjects and subjects with renal impairment with a Glomerular Filtration Rate (GFR) of 50-80 ml/min/1.73m2, 30-\<50 ml/min/1.73m2, \<30 ml/min/1.73m2 will be included in the study.
* The subjects must have a BMI between 19 and 32 kg/m2.

Exclusion Criteria:

* The subject has a history of renal transplant or is undergoing dialyse treatment.
* The subject is, in the opinion of the investigator, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.
Gestational Diabetes Mellitus: "Placental-maternal Crosstalk and Future Health"

The GaP study is designed to close important knowledge gaps by:

1. exploring placental health and cellular ageing in GDM and the association with neonatal outcome
2. evaluating the effectiveness of current and novel maternal health follow-up strategies after GDM

The incidence of gestational diabetes mellitus (GDM) is increasing. GDM has potential adverse short and long term health effects for both the women and her offspring, and involves dysfunctional interaction between placenta and the maternal body. The burden for the individual, the health system and society warrants further investigations into the placental-maternal crosstalk in GDM in order to improve personalized pregnancy surveillance and follow-up. In Oslo county, nearly twice as many women who give birth suffer from GDM (5.7%) than from preeclampsia (2.3%). The large obstetric department at Ullevål provides an optimal environment for novel translational studies and clinical practical aspects of GDM. The GaP study is designed to close important knowledge gaps by:

1. exploring placental health and cellular ageing in GDM and the association with neonatal outcome
2. evaluating the effectiveness of current and novel maternal health follow-up strategies after GDM

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women \>18 years with GDM giving birth at Oslo University hospital Ullevål.
* Control group of gestational age matched euglycemic, normotensive pregnancies

Exclusion Criteria:

* reduced fetal movements,
* epilepsy
* thyroidea dysfunction
* hypertensive disorder of pregnancy
* non-communicable disease
* Communicable disease (such as HIV)
* type 1 or type 2 diabetes.
* not able to understand Norwegian or English.
* under legal guardianship.
Preservation of Inferior Mesenteric Artery Could Improve Sexual Function After Laparoscopic Colorectal Resection for Diverticular Disease

This study aims to evaluate whether IMA sparing may represent an advantage in terms of reduced incidence and severity of sexual dysfunctions after colorectal resections for diverticular disease (DD).

Enrolled patients were randomly divided into 2 treatment groups. In the first group (IMAP) the IMA was preserved sectioning the sigmoid arteries near colonic wall while, in the second group (IMAS) the IMA was sectioned immediately below the origin of the left colic artery. Incidence and severity of sexual dysfunction and QoL were assessed by four validated questionnaire administered 6,12 months and 5 and 8 years after surgery.

Eligibility Criteria:
Inclusion Criteria:

* diverticular disease
* Diverticulitis
* BMI under 35 Kg/mq
* ASA score from I to III
* Standardized sigmoid, left colon or rectal resection

Exclusion Criteria:

* complicated diverticulitis (Hinchey III-IV)
* previous abdominal surgery or prostatic and/or gynecological resections
* adverse local condition or the need of multiorgan resection or stoma creation
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315

Primary: To assess the safety and tolerability of ascending multiple oral doses of SAM-315, an investigational drug, in healthy young adult and elderly subjects.

Secondary: To assess the Pharmacokinetic and Pharmacodynamic profiles of multiple oral doses of SAM-315 in healthy young adult and elderly subjects.


Eligibility Criteria:
Inclusion Criteria:

Young healthy subjects:

* Men and women of nonchildbearing potential (WONCBP) aged 18 to 45 years inclusive on study day 1.
* Body mass index (BMI) in the range of 18 to 30 kg/m2 and body weight greater than or equal to 50 kg and body weight greater than or equal to 50 kg.

Elderly Healthy subjects:

* Men or women aged 65 years and above as of study day 1.
* BMI in the range of 18 to 30 kg/m2 and body weight greater than or equal to 45 kg and body weight greater than or equal to 45 kg.

Exclusion Criteria:

* Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
* History of any clinically important drug allergy.
Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions

The aim of the study is evaluate the fusion ultrasound performance compared to MRI and coelioscopy diagnosis when a surgical intervention is performed.

The research is about diagnosis performance between fusion ultrasound and the gold standard (MRI coelioscopy ). Fusion ultrasound is a no-invasive scientific technical which allow with security to evaluate the progress of endometriosis lesions. During 39 months, 200 patients will be follow. In one arm, there is the control group with women without endometriosis. In the second arm, there is the patient with endometriosis. We will compare monitoring differences between gold standard and fusion ultrasound ( Cost assessment,exams duration, reproductibility, the link between symptoms and evolution of the lesion size).

Eligibility Criteria:
Inclusion Criteria:

* Patients from 18 to 50 years old
* Patient informed and who gave her non-opposition to participate in the research
* Patient with an indication for pelvic MRI and pelvic ultrasound either for the exploration of endometriosis or pelvic pain, or for another gynaecological pathology (ovarian cyst, poly-myomatous uterus, uterine malformation) outside of a proven cancer indication.
* Patient affiliated to a social security or entitled to a social security allowance

Exclusion Criteria:

* Patient with a proven cancerous pathology at the time of the prescription of the complementary examinations.
* Virgin patient
* Pregnant patient
* Patients under protective measures
* Contraindication to MRI (claustrophobia, intracorporeal metallic foreign body)
Feasibility of Continuous Noninvasive Finger Arterial Blood Pressure Measurement for Detection and Staging of Aortic Stenosis

The primary purpose of this study is electronic data collection of arterial pressure waveform signals in patients with Aortic Stenosis. The collected digital pressure waveform data will be used to assess the feasibility of using the arterial pressure signal as a decision support tool for early detection of aortic stenosis conditions. Furthermore we evaluate hemodynamic parameters before and after valve repair and its correlation with outcome.


Eligibility Criteria:
Inclusion Criteria:

* o Patients with severe senile degenerative aortic valve stenosis

  * Clinical team agrees on eligibility including assessment that TAVR is appropriate for the subject
  * Patients undergoing TAVR via the femoral approach
  * Patients who normally require a guiding catheter for central aortic pressure monitoring during the TAVR procedure
  * Patient must be 18 years old or older
  * Patient, or legally authorized representative, has given consent to be in the study
  * Patient height and weight are available prior to study
  * Ability to perform a Nexfin measurement at the left hand side.

Exclusion Criteria:

* o Patients with contraindications for placement of aortic catheter

  * Patients with mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+).
  * Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is noncalcified
  * Patients being treated with an intra-aortic balloon pump
  * Patients less than 40 kg in weight
  * Female patients of childbearing potential with a known pregnancy
  * Patient is currently participating in an investigational drug or another device study that clinically interferes with the study endpoints
Screening of Malignant Hyperthermia Susceptible Individuals

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing surgery under general anesthesia during the study period developed malignant hyperthermia during or after surgery.

Exclusion Criteria:

* Malignant hyperthermia was ruled out by later treatment and diagnosis;
* The patient or family member refuses to be recruited.
Concentrated Exposure and Response Prevention for Children With Obsessive-compulsive Disorder

The goal of this clinical trial is to evaluate the preliminary outcomes of concentrated exposure and response prevention for children with obsessive-compulsive disorder (OCD) in regular clinical practice. It is a non-randomised open label evaluation where children 6-12 years with OCD who are patients at the Child and Adolescent Psychiatry (CAP) at Uppsala University Hospital will be rectruited together with their legal guardians. The treatment will be delivered by trained therapists in regular outpatient care.

The main question the study aims to answer is:

What are the preliminary treatment effects of concentrated exposure and response prevention with regards to OCD-symptoms, functional impact, family accomodation and clinician ratings of severity and improvement?

Participants will receive psychoeducation (in group format) and exposure and response prevention (9-12h concentrated to one week, individual format).

Outcomes will be measured on structured interviews, clinician ratings, and validated questionnaires pre-treatment, post-treatment and at a six month follow-up.


Eligibility Criteria:
Inclusion Criteria:

* The patient fulfills the diagnostic criteria of obsessive-compulsive disorder
* The patient and the legal guardians have said yes to receiving the concentrated exposure with response prevention - treatment

Exclusion Criteria:

* The patient/legal guardians are unable to communicate in Swedish
Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder

The purpose of this study is to compare the effectiveness of two care models on ADHD outcomes: one, a model of basic care management and structured communication with specialists, consistent with conventional descriptions of a patient-centered Medical Home; and another, which combines the Medical Home with theory-based care management strategies to address common reasons for ADHD treatment failure.


Eligibility Criteria:
Inclusion Criteria:

* Child is being evaluated for a potential diagnosis of ADHD by a primary care pediatrician at one of our sites.
* Child is 6 to 12 years of age
* Family plans to remain in the Boston area for the duration of the follow-up period
* Mother is comfortable in English or Spanish

Exclusion Criteria:

* Child already has a confirmed diagnosis of ADHD
* Child already receives ongoing specialty care in one or more of the following clinics: pediatric psychiatry, developmental behavioral pediatrics
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone. It is not yet known if radiation therapy is more effective with or without bicalutamide and goserelin in treating prostate cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide and goserelin in treating patients who have localized prostate cancer.

OBJECTIVES:

* Compare the potential beneficial impact of radiotherapy with or without adjuvant bicalutamide and goserelin on the long-term outcome of patients with localized prostate cancer.
* Compare the acute and late radiation-induced side effects of these regimens in these patients.
* Compare the biochemical/clinical disease-free survival, overall survival, and time to local progression in patients treated with these regimens.
* Compare the time to clinical biological failure or death in patients treated with these regimens.
* Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor class (T1b-c vs T2a), initial prostate-specific antigen level (10 ng/mL vs 10-20 ng/mL vs greater than 20 ng/mL), Gleason score (2-6 vs 7-10) and participating center. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for 7-7.5 weeks.
* Arm II: Patients receive adjuvant oral bicalutamide once daily on days 1-30 and goserelin subcutaneously on days 8 and 98. Beginning on day 8, patients undergo radiotherapy as in arm I.

Quality of life is assessed at baseline and then at months 6, 12, 24, and 36.

Patients are followed every 6 months for 5 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 800 patients (400 per treatment arm) will be accrued for this study within 5 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed stage II prostate cancer

  * T1b-c, N0, M0 with prostate-specific antigen (PSA) at least 10 ng/mL and/or Gleason score at least 7 (UICC 1997 classification) OR
  * T2a, N0, M0 (UICC 1997 classification)
* Serum PSA no greater than 50 ng/mL
* No involvement of pelvic lymph nodes

PATIENT CHARACTERISTICS:

Age:

* 80 and under

Performance status:

* WHO 0-2

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

Other:

* No other malignancy within the past 5 years except adequately treated basal cell skin cancer
* No psychological, familial, sociological, or geographical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Not specified

Endocrine therapy:

* No prior hormonal therapy

Radiotherapy:

* No prior pelvic radiotherapy

Surgery:

* No prior radical prostatectomy
Liver Diseases in PLWH

In Highly Active Antiretroviral Therapy era, fatty liver has become an important cause of liver function damage in people living with HIV (PLWH). There are a large number of PLWH in China who are infected with hepatitis B virus and hepatitis C virus. HIV, hepatitis B virus, hepatitis C virus, drugs, alcohol, etc. affect each other, which makes the cause, diagnosis, and treatment of liver function damage in PLWH complicated in China.

The investigators plan to conduct a large-scale questionnaire survey among PLWH in Zhejiang Province to assess liver function, detect liver Injuries early, and analyze HIV, hepatitis B virus, hepatitis C virus, anti-HIV drugs, alcohol and other factors associate with liver injuries in PLWH, to provide basis for the treatment and prevention of liver disease in PLWH in eastern China.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years old;
* Non-hospitalized patients diagnosed with HIV infection;
* Sign the informed consent voluntarily.

Exclusion Criteria:

* Severe active infection requiring parenteral antibiotics or antifungal treatment within 30 days before the assessment;
* Other major chronic diseases that may affect health-related quality of life, such as extrahepatic malignant tumors;
* Psychotic patients, patients with severe cognitive or neurological deficits;
* Women during pregnancy and lactation;
* Those who refuse to sign informed consent.